Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade

Introduction

Upanovimab is a biosimilar of the Anti-Spike RBD mAb, which is a monoclonal antibody targeting the receptor binding domain (RBD) of the spike protein of SARS-CoV-2, the virus responsible for the ongoing COVID-19 pandemic. Upanovimab is a research grade antibody that has shown promising results in pre-clinical studies and is currently being evaluated for its potential as a therapeutic agent for COVID-19. In this article, we will discuss the structure, activity, and potential applications of Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade.

Structure of Upanovimab Biosimilar

Upanovimab Biosimilar is a monoclonal antibody produced through recombinant DNA technology. It is a humanized IgG1 antibody, meaning it has been engineered to have a human-like structure to minimize potential immune reactions in patients. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains, connected by disulfide bonds. The variable regions of the antibody, responsible for binding to the RBD of the spike protein, are derived from a human antibody sequence, while the constant regions are from a mouse antibody. This allows Upanovimab to retain its specificity and affinity for the RBD while also having a human-like structure.

Activity of Upanovimab Biosimilar

Upanovimab Biosimilar specifically targets the RBD of the spike protein of SARS-CoV-2. The spike protein is responsible for the virus’s entry into host cells, and the RBD is the region of the spike protein that binds to the ACE2 receptor on human cells. By binding to the RBD, Upanovimab prevents the virus from attaching to and infecting host cells. In pre-clinical studies, Upanovimab has been shown to effectively neutralize SARS-CoV-2 and inhibit its replication. This activity makes Upanovimab a potential therapeutic agent for COVID-19.

Application of Upanovimab Biosimilar

Upanovimab Biosimilar is currently being evaluated for its potential as a therapeutic agent for COVID-19. It is being studied as a potential treatment for both mild and severe cases of the disease. In mild cases, Upanovimab could potentially prevent the progression of the disease and reduce the severity of symptoms. In severe cases, Upanovimab could potentially reduce the viral load and prevent further damage to the lungs and other organs. Additionally, Upanovimab could also be used as a prophylactic treatment for high-risk individuals, such as healthcare workers, to prevent infection with SARS-CoV-2.

Future Potential of Upanovimab Biosimilar

Apart from its potential as a therapeutic agent for COVID-19, Upanovimab Biosimilar could also have potential applications in other diseases caused by coronaviruses. The RBD of the spike protein is highly conserved among coronaviruses, and Upanovimab could potentially be effective against other strains of coronavirus, such as the SARS-CoV-1 virus that caused the 2002-2004 SARS outbreak. Upanovimab could also have potential applications in future outbreaks of novel coronaviruses, as it could be quickly adapted to target the RBD of the specific virus.

Conclusion

Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade is a promising antibody that specifically targets the RBD of the spike protein of SARS-CoV-2. Its humanized structure and potent activity against the virus make it a potential therapeutic agent for COVID-19. Further studies and clinical trials will determine its efficacy and safety in treating and preventing COVID-19. Upanovimab could also have potential applications in other diseases caused by coronaviruses, making it a valuable asset in the fight against future outbreaks.

ProteoGenix catalogue number PX-TA1798. For research use only.

Target: Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet